North America Cancer Immunotherapy Market Size & Outlook
- Pharmaceuticals
- Oncology Drugs
- Cancer Immunotherapy Market Outlook
- Oncology Drugs
Global Market
Related Markets
Ask a question about the cancer immunotherapy market
North America cancer immunotherapy market highlights
- The North America cancer immunotherapy market generated a revenue of USD 66,304.2 million in 2025.
- The market is expected to grow at a CAGR of 8.3% from 2026 to 2033.
- In terms of segment, monoclonal antibodies was the largest revenue generating product in 2025.
- Oncolytic Viral Therapies and Cancer Vaccines is the most lucrative product segment registering the fastest growth during the forecast period.
- Country-wise, Mexico is expected to register the highest CAGR from 2026 to 2033.
North America data book summary
| Market revenue in 2025 | USD 66,304.2 million |
| Market revenue in 2033 | USD 124,762.5 million |
| Growth rate | 8.3% (CAGR from 2026 to 2033) |
| Largest segment | Monoclonal antibodies |
| Fastest growing segment | Oncolytic Viral Therapies and Cancer Vaccines |
| Historical data covered | 2021 - 2024 |
| Base year for estimation | 2025 |
| Forecast period covered | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Monoclonal Antibodies, Check Point Inhibitors, Oncolytic Viral Therapies and Cancer Vaccines |
| Key market players worldwide | Pfizer Inc, AstraZeneca PLC, Merck & Co Inc, Roche Holding AG, Bristol-Myers Squibb Co, Novartis AG ADR, Eli Lilly and Co, Johnson & Johnson, Immunocore Holdings PLC ADR |
Other key industry trends
- In terms of revenue, North America region accounted for 43.3% of the global cancer immunotherapy market in 2025.
- Globally, North America is projected to lead the regional market in terms of revenue in 2033.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 71,890.9 million by 2033.
High growth of the cancer immunotherapy market in North America can be attributed to various factors, such as rise in burden of cancer and increase in number of favorable government initiatives. Funding for cancer research is high in the region. Moreover, increasing demand for personalized medicines is expected to positively impact growth of the North American cancer immunotherapy market.
Moreover, government regulations in North America support R&D for novel cancer immune therapeutics. Major players operating in this market are Merck & Co., Inc.; Bristol-Myers Squibb Company; and F. Hoffmann-La Roche Ltd. Presence of some of the leading companies is expected to increase availability of cancer immune therapeutics in the region.
For instance, in May 2017, the U.S. FDA approved Keytruda (Merck & Co., Inc.) for cancer patients with certain specific biomarkers. North America holds a major market share, especially the U.S., due to increasing awareness about the potential of immunotherapy and targeted therapy. This factor has driven the U.S.-based firms to make considerable investments in the development of novel drugs.
No credit card required*
Publish Date: Dec 03, 2025
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cancer Immunotherapy Market Scope
Cancer Immunotherapy Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Johnson & Johnson | View profile | 134,400 | One Johnson and Johnson Plaza, New Brunswick, NJ, United States, 08933 | www.jnj.com |
| Novartis AG ADR | View profile | 76,057 | Lichtstrasse 35, Basel, Switzerland, 4056 | www.novartis.com |
| Pfizer Inc | View profile | 88,000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | www.pfizer.com |
| Roche Holding AG | View profile | 103,605 | Grenzacherstrasse 124, Basel, Switzerland, 4070 | www.roche.com |
| Merck & Co Inc | View profile | 72,000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | www.merck.com |
| Bristol-Myers Squibb Co | View profile | 34,100 | Route 206 and Province Line Road, Princeton, New Jersey, NJ, United States, 08543 | www.bms.com |
| Eli Lilly and Co | View profile | 43,000 | Lilly Corporate Center, Indianapolis, IN, United States, 46285 | www.lilly.com |
| AstraZeneca PLC | View profile | 89,900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | www.astrazeneca.com |
| Immunocore Holdings PLC ADR | View profile | 497 | 92 Park Drive, Milton Park, Abingdon, Oxfordshire, United Kingdom, OX14 4RY | www.immunocore.com |
North America Cancer Immunotherapy Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Cancer Immunotherapy Market Outlook will help companies and investors design strategic landscapes.
Monoclonal Antibodies was the largest segment with a revenue share of 63.11% in 2025.
Horizon Databook has segmented the North America cancer immunotherapy market based on monoclonal antibodies, check point inhibitors, oncolytic viral therapies and cancer vaccines covering the revenue growth of each sub-segment from 2021 to 2033.
High growth of the cancer immunotherapy market in North America can be attributed to various factors, such as rise in burden of cancer and increase in number of favorable government initiatives. Funding for cancer research is high in the region. Moreover, increasing demand for personalized medicines is expected to positively impact growth of the North American cancer immunotherapy market.
Moreover, government regulations in North America support R&D for novel cancer immune therapeutics. Major players operating in this market are Merck & Co., Inc.; Bristol-Myers Squibb Company; and F. Hoffmann-La Roche Ltd. Presence of some of the leading companies is expected to increase availability of cancer immune therapeutics in the region.
For instance, in May 2017, the U.S. FDA approved Keytruda (Merck & Co., Inc.) for cancer patients with certain specific biomarkers. North America holds a major market share, especially the U.S., due to increasing awareness about the potential of immunotherapy and targeted therapy. This factor has driven the U.S.-based firms to make considerable investments in the development of novel drugs.
- North America Cancer Immunotherapy Market Product Outlook (Revenue, USD Million , 2021-2033)
- Monoclonal Antibodies
- Check Point Inhibitors
- Oncolytic Viral Therapies and Cancer Vaccines
- North America Cancer Immunotherapy Market Application Outlook (Revenue, USD Million , 2021-2033)
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Melanoma
- Prostate Cancer
- Head and Neck Cancer
- Ovarian Cancer
- Pancreatic Cancer
- Other Applications
- North America Cancer Immunotherapy Market Distribution Channel Outlook (Revenue, USD Million , 2021-2033)
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- North America Cancer Immunotherapy Market End Use Outlook (Revenue, USD Million , 2021-2033)
- Hospitals and Clinics
- Cancer Research Centers
- Other End users
Reasons to subscribe to Cancer Immunotherapy Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Cancer Immunotherapy Market Outlook databook
- Our clientele includes a mix of Cancer Immunotherapy Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America Cancer Immunotherapy Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into North America Cancer Immunotherapy Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
North America Cancer Immunotherapy Market, 2021-2033 (US$M)
North America cancer immunotherapy market statistics, by product, 2021-2033 (US$M)
